Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429721 | 0.91 | PDK2 (0.32) | PDK2PTGER4PTGER3PTGER2 | |
| SCHEMBL3429397 | 0.89 | PDK2 (0.43) | PDK2PTGER4PTGER3PTGER2 | |
| SCHEMBL3429723 | 0.85 | PDK2 (0.41) | PDK2PTGER4PTGER3PTGER2 | |
| SCHEMBL3428236 | 0.80 | — | — | |
| SCHEMBL3429111 | 0.77 | PTGER4 (0.38) | PDK2PTGER4PTGER3PTGER2 | |
| SCHEMBL3429891 | 0.71 | S1PR1 (0.45) | — | |
| SCHEMBL3427414 | 0.70 | — | — | |
| SCHEMBL3428238 | 0.69 | — | — | |
| SCHEMBL1712646 | 0.67 | PDK2 (0.41) | PDK2PTGER4PTGER3PTGER2 | |
| SCHEMBL12298851 | 0.67 | MEN1 (0.44) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | PDK2 112/4885PTGER4 1125/4885PTGER3 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.